Uvax Bio elevated Chief Business Officer Kevin O’Neill to Interim CEO following the departure of Ji Li, Ph.D., …
Uvax Bio elevated Chief Business Officer Kevin O’Neill to Interim CEO following the departure of Ji Li, Ph.D., …
Novartis confirmed its acquisition of Anthos Therapeutics for up to $3.1 billion—securing a promising Phase III-stage anticoagulant aimed at …
Parexel reveals strategic plans to ramp up its Indian operations—underscoring India’s emerging prominence as a critical node in …
On February 1, 2025, the U.S. Food and Drug Administration (FDA) approved Eli Lilly’s lebrikizumab, marking the first …
Johnson & Johnson discontinues three neuroscience programs—including the sleep-focused seltorexant—realigning its R&D priorities and signaling a strategic course …
Vertex Pharmaceuticals earns approval for JOURNAVX™ (suzetrigine), a ground-breaking oral NaV1.8 pain channel inhibitor designed to target moderate-to-severe …
January’s investment activity saw a wave of biotech Series funding, with Verdiva Bio, Aviceda Therapeutics, Windward Bio, and …
Atalanta Therapeutics raises $97 million in Series B funding to accelerate RNA interference therapies into Phase 1 trials, …
Allakos faced a major setback as its chronic hives drug AK006 failed to outperform placebo in a key …
Sarepta Therapeutics reports encouraging Phase III trial data for Elevidys, its AAV-based gene therapy for Duchenne muscular dystrophy, …